{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T01:01:30Z","timestamp":1767142890349,"version":"build-2238731810"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T00:00:00Z","timestamp":1602892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T00:00:00Z","timestamp":1602892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s11739-020-02528-4","type":"journal-article","created":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T08:03:19Z","timestamp":1602921799000},"page":"895-903","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Management of patients with chronic heart failure and type 2 diabetes mellitus: the SCODIAC-II study"],"prefix":"10.1007","volume":"16","author":[{"given":"Mariarosaria","family":"De Luca","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Bosso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Valvano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Guardasole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amodio","family":"Botta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Carella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Del Buono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Di Giovanni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biagio","family":"Fimiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franco","family":"Guarnaccia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuela","family":"Lapice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilia","family":"Marted\u00ec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Memoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenica","family":"Oliva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geremia","family":"Romano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Cittadini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni Battista","family":"Zito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ugo","family":"Oliviero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,17]]},"reference":[{"key":"2528_CR1","first-page":"e139","volume":"141","author":"SS Virani","year":"2020","unstructured":"Virani SS, Alonso CA, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP et al (2020) heart disease and stroke statistics\u20142020 update a report from the American Heart Association. Circulation 141:e139\u2013e596","journal-title":"Circulation"},{"key":"2528_CR2","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1177\/1479164118794619","volume":"15","author":"I Johansson","year":"2018","unstructured":"Johansson I, Dahlstr\u00f6m U, Edner M, N\u00e4sman P, Ryd\u00e9n L, Norhammar A (2018) Type 2 diabetes and heart failure: characteristics and prognosis in preserved, mid-range and reduced ventricular function. Diab Vasc Dis Res 15:494\u2013503","journal-title":"Diab Vasc Dis Res"},{"key":"2528_CR3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/0002-9149(74)90089-7","volume":"34","author":"WB Kannel","year":"1974","unstructured":"Kannel WB, Hjortland M, Castelli WP (1974) Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 34:29\u201334","journal-title":"Am J Cardiol"},{"key":"2528_CR4","first-page":"605","volume":"5","author":"L Tarantini","year":"2004","unstructured":"Tarantini L, Di Lenarda A, Velussi M, Faggiano P, Comaschi M, Faglia E et al (2004) Diabetes mellitus, left ventricular dysfunction and congestive heart failure. Ital Heart J 5:605\u2013615","journal-title":"Ital Heart J"},{"key":"2528_CR5","first-page":"219","volume":"4","author":"A Botta","year":"2019","unstructured":"Botta A, Carbone V, Carella G, Del Buono A, De Luca M, Di Giovanni G et al (2019) Scompenso cardiaco nel paziente con diabete in Campania (SCODIAC). The Journal of AMD 4:219\u2013229","journal-title":"The Journal of AMD"},{"key":"2528_CR6","doi-asserted-by":"publisher","first-page":"216","DOI":"10.2459\/JCM.0000000000000940","volume":"21","author":"G Bosso","year":"2020","unstructured":"Bosso G, Valvano A, Guarnaccia F, Fimiani B, Carbone V, Cittadini A et al (2020) Adherence to guidelines in the management of patients with chronic heart failure follow-up: role of periodic echocardiographic examinations. J Cardiovasc Med 21:216\u2013222","journal-title":"J Cardiovasc Med"},{"key":"2528_CR7","doi-asserted-by":"crossref","unstructured":"American Diabetes Association. Microvascular Complications and Foot Care:\u00a0Standards of Medical Care in Diabetes (2018) Diabetes Care. 41(Suppl 1):S105-S118.","DOI":"10.2337\/dc18-S010"},{"key":"2528_CR8","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1161\/CIRCHEARTFAILURE.112.000162","volume":"6","author":"DT Eurich","year":"2013","unstructured":"Eurich DT, Weir DL, Majumdar SR, Tsuyuki RT, Johnson JA, Tjosvold L et al (2013) Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. Circ Heart Fail 6:395\u2013402","journal-title":"Circ Heart Fail"},{"key":"2528_CR9","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00592-008-0090-3","volume":"46","author":"KM Pantalone","year":"2009","unstructured":"Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A et al (2009) The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis. Acta Diabetol 46:145\u2013154","journal-title":"Acta Diabetol"},{"key":"2528_CR10","doi-asserted-by":"publisher","first-page":"b4731","DOI":"10.1136\/bmj.b4731","volume":"339","author":"I Tzoulaki","year":"2009","unstructured":"Tzoulaki I, Molokhia M, Curcin V, Little MP, Millett CJ, Ng A et al (2009) Risk of cardiovascular disease and all-cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 339:b4731","journal-title":"BMJ"},{"key":"2528_CR11","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","volume":"366","author":"JA Dormandy","year":"2005","unstructured":"Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK et al (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitazone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet 366:1279\u20131289","journal-title":"Lancet"},{"key":"2528_CR12","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","volume":"369","author":"BM Scirica","year":"2013","unstructured":"Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B et al (2013) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369:1317\u20131326","journal-title":"N Engl J Med"},{"key":"2528_CR13","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","volume":"369","author":"WB White","year":"2013","unstructured":"White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL et al (2013) Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369:1327\u20131335","journal-title":"N Engl J Med"},{"key":"2528_CR14","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1056\/NEJMoa1501352","volume":"37","author":"JB Green","year":"2015","unstructured":"Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J et al (2015) Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 37:232\u2013242","journal-title":"N Engl J Med"},{"key":"2528_CR15","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1093\/eurheartj\/ehv301","volume":"36","author":"GP Fadini","year":"2015","unstructured":"Fadini GP, Avogaro A, Degli Esposti L, Russo P, Saragoni S, Buda S et al (2015) Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database. Eur Heart J 36:2454\u20132462","journal-title":"Eur Heart J"},{"key":"2528_CR16","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1161\/CIRCHEARTFAILURE.114.000346","volume":"7","author":"KB Margulies","year":"2014","unstructured":"Margulies KB, Anstrom KJ, Hernandez AF, Redfield MM, Shah MR, Braunwald E et al (2014) GLP-1 agonist therapy for advanced heart failure with reduced ejection fraction: design and rationale for the functional impact of GLP-1 for heart failure treatment study. Circ Heart Fail 7:673\u2013679","journal-title":"Circ Heart Fail"},{"key":"2528_CR17","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA et al (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375:311\u2013322","journal-title":"N Engl J Med"},{"key":"2528_CR18","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, SEMPA-REGOUTCOME Hantel Investigators et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117\u20132128","journal-title":"N Engl J Med"},{"key":"2528_CR19","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377:644\u2013657","journal-title":"N Engl J Med"},{"key":"2528_CR20","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380:347\u2013357","journal-title":"N Engl J Med"},{"key":"2528_CR21","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1161\/CIRCULATIONAHA.119.040130","volume":"139","author":"ET Kato","year":"2019","unstructured":"Kato ET, Silverman MG, Mosenzon O, Zelniker TA, Cahn A, Furtado RHM et al (2019) Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation 139:2528\u20133253","journal-title":"Circulation"},{"key":"2528_CR22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"TA Zelniker","year":"2018","unstructured":"Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP et al (2018) SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393:31\u201339","journal-title":"Lancet"},{"key":"2528_CR23","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1161\/CIRCULATIONAHA.117.029190","volume":"136","author":"M Kosiborod","year":"2017","unstructured":"Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW et al (2017) Lower risk of heart failure and death in patients initiated on SGLT-2 inhibitors versus other glucose lowering drugs: the CVD-REAL Study. Circulation 136:249\u2013259","journal-title":"Circulation"},{"key":"2528_CR24","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381:1995\u20132008","journal-title":"N Engl J Med"},{"key":"2528_CR25","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1002\/ehf2.12505","volume":"6","author":"SR Lan","year":"2019","unstructured":"Lan SR, Fegan PG, Yeap BB, Dwivedi G (2019) The effects of sodium-glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions. ESC Heart Failure 6:927\u2013935","journal-title":"ESC Heart Failure"},{"key":"2528_CR26","first-page":"A17041","volume":"136","author":"T Sakai","year":"2018","unstructured":"Sakai T, Miura S (2018) Effect of sodium-glucose cotransporter 2 inhibitor on vascular endothelial function and diastolic function in patients with heart failure with preserved ejection fraction (HF-pEF). Circulation 136:A17041","journal-title":"Circulation"},{"key":"2528_CR27","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12933-018-0775-z","volume":"17","author":"F Soga","year":"2018","unstructured":"Soga F, Tanaka H, Tatsumi K, Mochizuki Y, Sano H, Toki H et al (2018) Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure. Cardiovasc Diabetol 17:132","journal-title":"Cardiovasc Diabetol"},{"issue":"10","key":"2528_CR28","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1002\/ejhf.1531","volume":"21","author":"PM Seferovic","year":"2019","unstructured":"Seferovic PM, Ponikowski P, Anker SD, Bauersachs J, Chioncel O, Cleland JGF et al (2019) Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 21(10):1169\u20131186","journal-title":"Eur J Heart Fail"},{"key":"2528_CR29","doi-asserted-by":"publisher","first-page":"491","DOI":"10.2459\/JCM.0000000000000038","volume":"15","author":"F Guarnaccia","year":"2014","unstructured":"Guarnaccia F, Fimiani B, Zito GB, De Simone A, Stabile G, Bossone E et al (2014) ALERT-HF: adherence to guidelines in the treatment of patients with chronic heart failure. J Cardiovasc Med 15:491\u2013497","journal-title":"J Cardiovasc Med"},{"key":"2528_CR30","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","volume":"41","author":"F Cosentino","year":"2020","unstructured":"Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V et al (2020) ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD European Heart Journal, 2019. Eur Heart J 41:255\u2013323","journal-title":"Eur Heart J"}],"updated-by":[{"DOI":"10.1007\/s11739-021-02845-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T00:00:00Z","timestamp":1632873600000}}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-020-02528-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11739-020-02528-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-020-02528-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,29]],"date-time":"2021-12-29T06:11:43Z","timestamp":1640758303000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11739-020-02528-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,17]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["2528"],"URL":"https:\/\/doi.org\/10.1007\/s11739-020-02528-4","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,17]]},"assertion":[{"value":"11 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s11739-021-02845-2","URL":"https:\/\/doi.org\/10.1007\/s11739-021-02845-2","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest\/competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest\/Competing interests"}},{"value":"The protocol was approved by the University of Naples Federico II Ethics Committee and registered at <i>ClinicalTrial.gov<\/i> (CT04375943). The principles outlined in the Declaration of Helsinki were followed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement of human and animal rights"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}